ANPAC BIO-MEDICAL SCIENC-ADR (ANPC)

US03635R2067 - ADR

4.37  -0.25 (-5.41%)

Fundamental Rating

1

Taking everything into account, ANPC scores 1 out of 10 in our fundamental rating. ANPC was compared to 588 industry peers in the Biotechnology industry. ANPC may be in some trouble as it scores bad on both profitability and health. ANPC does not seem to be growing, but still is valued expensively.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ANPC has reported negative net income.
In the past 5 years ANPC always reported negative net income.
In the past 5 years ANPC always reported negative operating cash flow.

1.2 Ratios

ANPC has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ANPC has a better Gross Margin (78.61%) than 86.67% of its industry peers.
In the last couple of years the Gross Margin of ANPC has grown nicely.
The Profit Margin and Operating Margin are not available for ANPC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 78.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y15.1%
GM growth 5YN/A

More info and screens

0

2. Health

2.1 Basic Checks

ANPC does not have a ROIC to compare to the WACC, probably because it is not profitable.
ANPC has more shares outstanding than it did 1 year ago.
ANPC has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -4.52, we must say that ANPC is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.52, ANPC is doing worse than 64.60% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.52
ROIC/WACCN/A
WACC7.66%

2.3 Liquidity

A Current Ratio of 0.66 indicates that ANPC may have some problems paying its short term obligations.
ANPC has a worse Current ratio (0.66) than 90.95% of its industry peers.
A Quick Ratio of 0.65 indicates that ANPC may have some problems paying its short term obligations.
ANPC's Quick ratio of 0.65 is on the low side compared to the rest of the industry. ANPC is outperformed by 90.63% of its industry peers.
Industry RankSector Rank
Current Ratio 0.66
Quick Ratio 0.65

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 29.36% over the past year.
ANPC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -47.20%.
ANPC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.62% yearly.
EPS 1Y (TTM)29.36%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q72.17%
Revenue 1Y (TTM)-47.2%
Revenue growth 3Y20.62%
Revenue growth 5YN/A
Revenue growth Q2Q44.53%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ANPC. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ANPC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANPAC BIO-MEDICAL SCIENC-ADR

NASDAQ:ANPC (5/19/2023, 7:11:20 PM)

4.37

-0.25 (-5.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap180.61M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 78.61%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.66
Quick Ratio 0.65
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)29.36%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-47.2%
Revenue growth 3Y20.62%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y